



PRESS RELEASE

Adocia announces its financial calendar for 2015

Lyon, France, December 29, 2014 - Adocia (Euronext Paris: FR0011184241 - ADOC), a biotechnology company specialized in the development of 'best-in-class' medicines from already approved therapeutics proteins, announces today its financial calendar for 2015.

- | | |
|---------------------------|--|
| February 17, 2015: | Publication of revenue for Q4 2014 and for 2014 full year. |
| March 10, 2015: | Publication of 2014 financial statements (the Reference Document will be released during Q2 2015). |
| April 14, 2015: | Publication of revenue for Q1 2015. |
| May 27, 2015: | Annual shareholders' meeting at Château Montchat, Lyon 3°. |
| July 21, 2015: | Publication of mid-year financial statements as of June 30, 2015. |
| October 13, 2015: | Publication of revenue for Q3 2015. |

In addition to regular meetings with the financial community, investors can also find updated information on the company's website (www.adocia.com). All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company's website, in the Investors' section, « Regulated Information ».

About Adocia:

To be a global leader in the innovative delivery of insulins and therapeutic proteins

ADOCIA is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. ADOCIA's proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, ADOCIA signed a partnership with the company Eli Lilly for the development of its new formulation of insulin lispro, BioChaperone Lispro, tested successfully in two phase IIa studies.

ADOCIA will continue to pursue development of its fast-acting human insulin formulation alone. The phase IIa clinical results are expected in first trimester 2015.

ADOCIA is actively continuing the development of its BioChaperone Combo, a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. A dose-response clinical study (Phase IIa) is scheduled for Q1 2015.

In August 2014, ADOCIA also launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB).

ADOCIA has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). ADOCIA is engaged in collaborative programs with two major pharmaceutical companies in this field.

Fighting cancer with targeted treatments

DriveIn® is a nanotechnology which is remarkably efficient in delivering active compounds into cancer cells. This new platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

« Innovative medicine for everyone, everywhere »

ADOCIA's therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

ADOCIA is listed on the regulated market of Euronext Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech index.

American Depositary Receipts representing ADOCIA common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit: www.adocia.com

Contact ADOCIA

Gérard Soula - contactinvestisseurs@adocia.com

Chairman and CEO of ADOCIA

Tel.: +33 4 72 610 610



Press Relations

ALIZE RP

Caroline Carmagnol caroline@alizerp.com

adocia@alizerp.com

Tel.: + 33 1 44 54 36 61